World Health Organization & Mapp Biopharmaceutical

World Health Organization: The World Health Organization recommended prioritizing three experimental treatments and several vaccine candidates for the Bundibugyo strain of Ebola, and is working with authorities to design and implement clinical trials.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.

World Health Organization: Leading the international response, coordinating clinical trials, and issuing warnings; faces criticism over response speed.

Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.

World Health Organization: The WHO previously included ziresovir as the only therapeutic drug in its Paediatric Drug Optimization for RSV publication, lending credibility to the drug's potential.

Mapp Biopharmaceutical: ArkBio is the developer of ziresovir and the recipient of the FDA approval, marking a significant advancement in its lead pipeline asset and potentially increasing its commercial prospects.

World Health Organization: The World Health Organization>>> has declared the Ebola outbreak a public health emergency of international concern and is coordinating the international response, providing experts, supplies, and guidance, though it faces criticism for delayed detection and underestimation of the outbreak's scale.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.